Compare ORKA & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORKA | IMKTA |
|---|---|---|
| Founded | 2004 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 1994 |
| Metric | ORKA | IMKTA |
|---|---|---|
| Price | $45.54 | $87.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $57.25 | N/A |
| AVG Volume (30 Days) | ★ 504.1K | 101.5K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.76% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $5,334,032,609.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.49 | $59.09 |
| 52 Week High | $45.52 | $90.49 |
| Indicator | ORKA | IMKTA |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 58.79 |
| Support Level | $26.02 | $68.58 |
| Resistance Level | N/A | $89.76 |
| Average True Range (ATR) | 3.21 | 2.54 |
| MACD | 0.73 | -0.15 |
| Stochastic Oscillator | 89.39 | 86.00 |
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.